SCHEMBL1186459

SCHEMBL1186459

COc1ccc(COc2cccc(-c3nnc(C)o3)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
TP53 P04637 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
VDR P11473 5/20 0.48
PPARD Q03181 3/20 0.48
POLB P06746 1/20 0.48
SMPD1 P17405 1/20 0.48
ESR1 P03372 1/20 0.47
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
RXRA P19793 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10054151 0.84 KDM4E (0.69) KMT2AKDM4EMAPTRAB9ANPC1
SCHEMBL1630232 0.80 KDM4E (0.56) KMT2AKDM4EMAPTRAB9ANPC1
SCHEMBL10834901 0.76 TP53 (0.46) MAOBKMT2AKDM4EMAPTRAB9A
SCHEMBL10835842 0.75 TP53 (0.45) MAOBKMT2AKDM4EMAPTRAB9A
SCHEMBL3492223 0.75 GSK3B (0.53) MAOBKDM4EMAPTTP53ALDH1A1
SCHEMBL2360960 0.74 NPC1 (0.73) KMT2AKDM4EMAPTRAB9ANPC1
SCHEMBL1181062 0.74 KDM4E (0.78) KMT2AKDM4EMAPTRAB9ANPC1
SCHEMBL8111957 0.74 KDM4E (0.55) MAOBKMT2AKDM4EMAPTRAB9A
SCHEMBL21612778 0.73 POLB (0.62) MAOBKDM4EMAPTRAB9ANPC1
SCHEMBL11166490 0.73 ALDH1A1 (0.57) KMT2AKDM4EMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2297129-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2013-07-24 EP disclosed
EP-2297129-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2013-07-24 EP disclosed
US-8343990-B2 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. (US) 2013-01-01 US disclosed
US-8343990-B2 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. (US) 2013-01-01 US disclosed
US-20110028501-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME LLC 2011-02-03 US disclosed
US-20110028501-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME LLC 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028501-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR27, GPR139 MAOB 2243/4885KMT2A 4653/4885KDM4E 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.